NCT03899298View on ClinicalTrials.gov

Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

5,000

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

March 20, 2024

Study Completion Date

March 20, 2029

Conditions
Orthopedic DisorderNeurologic DisorderUrologic DiseasesErectile DysfunctionAutoimmune DiseasesRenal FailureRenal InsufficiencyKidney DiseasesCardiac EventCardiomyopathiesCHFPulmonary DiseaseCOPDAlzheimer DiseaseStrokeNeuropathy;PeripheralArthritis
Interventions
BIOLOGICAL

Amniotic and Umbilical Cord Tissue Procedure

Amniotic and Umbilical Cord Cell Therapy with protocols dependent on the patient condition. Protocols include options for IV, Injection, Intranasal and/or Nebulizer.

All Listed Sponsors
lead

R3 Stem Cell

INDUSTRY